Are Late-Stage Deals Driving Up the Cost of Preclinical Deals?
Executive Summary
With patent expirations looming, and Big Pharma pipelines unable to fill the gap, competition for late-stage licensing opportunities continues to drive late stage-deal valuations ever higher. But is this activity effectively pricing some licensors out of range, sending them instead to earlier-stage deals, and driving up prices there accordingly?
You may also be interested in...
In-Licensing in Specialty Pharma
The emerging sector of specialty pharma-companies building a business around in-licensing poorly penetrated drugs and growing their share through targeted sales efforts-represents an increasing percentage of total dealmaking volume. But could its strategy already be suffering from diminishing returns?
In-Licensing in Specialty Pharma
The emerging sector of specialty pharma-companies building a business around in-licensing poorly penetrated drugs and growing their share through targeted sales efforts-represents an increasing percentage of total dealmaking volume. But could its strategy already be suffering from diminishing returns?
Licensing Trends By Clinical Phase
We revisit a chart from 1997 examining deal volume by clinical phase to highlight the changing landscape of late stage licensing.